共 36 条
Recombinant human erythropoietin attenuates hepatic injury induced by ischemia/reperfusion in an isolated mouse liver model
被引:59
作者:
Hochhauser, Edith
[3
]
Pappo, Orit
[4
]
Ribakovsky, Evgeni
[5
]
Ravid, Amiram
[6
]
Kurtzwald, Efrat
[3
]
Cheporko, Yelena
[3
]
Lelchuk, Shlomo
[5
]
Ben-Ari, Ziv
[1
,2
]
机构:
[1] Tel Aviv Univ, Petah Tiqva & Sackler Sch Med, Rabin Med Ctr, Liver Inst, IL-69978 Tel Aviv, Israel
[2] Tel Aviv Univ, Petah Tiqva & Sackler Sch Med, Rabin Med Ctr, Dept Med D, IL-69978 Tel Aviv, Israel
[3] Tel Aviv Univ, Petah Tiqva & Sackler Sch Med, Rabin Med Ctr, Dept Cardiothorac Surg,Cardiac Res Lab, IL-69978 Tel Aviv, Israel
[4] Tel Aviv Univ, Petah Tiqva & Sackler Sch Med, Rabin Med Ctr, Dept Histopathol, IL-69978 Tel Aviv, Israel
[5] Tel Aviv Univ, Petah Tiqva & Sackler Sch Med, Rabin Med Ctr, Dept Surg B, IL-69978 Tel Aviv, Israel
[6] Tel Aviv Univ, Petah Tiqva & Sackler Sch Med, Rabin Med Ctr, Felsenstein Med Res Ctr,Endocrinol Immunol Lab, IL-69978 Tel Aviv, Israel
来源:
关键词:
apoptosis;
von Willebrand factor;
caspase-3;
erythropoietin;
ischemia/reperfusion;
iolated;
mouse;
liver;
D O I:
10.1007/s10495-007-0155-8
中图分类号:
Q5 [生物化学];
Q7 [分子生物学];
学科分类号:
071010 [生物化学与分子生物学];
081704 [应用化学];
摘要:
Introduction Apoptosis is a central mechanism of cell death following reperfusion of the ischemic liver. Recombinant human erythropoietin (rhEPO) have an important role in the treatment of myocardial ischemia/reperfusion (I/R) injury, by preventing apoptosis. The aim of the study was to investigate the effect of different regimens of rhEPO in preventing apoptosis following I/R-induced hepatic injury. Material and methods Isolated mouse livers were randomly divided into five groups: (1) control group, perfused for the whole study period (105 min); (2) 30-min perfusion followed by 90 min of ischemia and 15 min of reperfusion; (3), (4) and (5) like group 2, but with administration of rhEPO 5,000 units/kg i.p. at 30 min, 24 h, or both 30 min and 24 h respectively, before induction of ischemia. Perfusate liver enzyme levels and intrahepatic caspase-3 activity were measured, and apoptotic cells were identified by morphological criteria, TUNEL assay, and immunohistochemistry for caspase-3. Using immunoblot the expression of the proapoptotic JNK and inhibitor of NF kappa B (I kappa B alpha) were also evaluated. von Willebrand factor (vWF) immunohistochemistry was used as a marker of endothelial cells. Results Compared to the I/R livers, all 3 rhEPO pretreated groups showed: a significant reduction in liver enzyme levels (P < 0.05) and intrahepatic caspase-3 activity (P < 0.05), fewer apoptotic hepatocytes (P < 0.05) and positive vWF staining in numerous endothelial cells lining the sinusoids. EPO decreased JNK phosphorylation and the degradation of the inhibitor of NF kappa B (I kappa B alpha) during I/R. There was no added benefit of the multiple- over the single-dose rhEPO regimen. Conclusion Pretreatment with one dose of rhEPO can attenuate post-I/R hepatocyte apoptotic liver damage. NF kappa B and JNK activation is likely to play a pivotal role in the pathophysiology of I/R hepatic injury and might have a key role in EPO-mediated protective effects. This effect is associated with the increase in sinusoidal vWF immunostaining suggests an additional effect of rhEPO in liver angiogenesis recovery. These findings have important implications for the potential use of rhEPO in I/R injury during liver transplantation.
引用
收藏
页码:77 / 86
页数:10
相关论文

